PATTERNS OF DNA AMPLIFICATION AT BAND-Q13 OF CHROMOSOME-11 IN HUMAN BREAST-CANCER
PATTERNS OF DNA AMPLIFICATION AT BAND-Q13 OF CHROMOSOME-11 IN HUMAN BREAST-CANCER
复制标题
DOI：
10.1002/gcc.2870090108
复制
发表时间：
1994-01-01
影响因子：
3.7
通讯作者：
THEILLET, C
中科院分区：
文献类型：
--
作者：
KARLSEDER, J;ZEILLINGER, R;THEILLET, C
为了验证 11 号染色体上 q13 条带扩增事件的性质，我们调查了 389 个原发乳腺样本中该区域特异的 10 个分子标记（GSTP、SEA、D11S97、D11S146、BCL1、PRAD1/CCND1、HST/FGF4、INT2/FGF3、EMS1 和 D11S833E）的扩增状态。 癌DNA样本。 88 个肿瘤 (23%) 至少显示其中一种标记物被扩增，但在大多数情况下，扩增涵盖了多个测试基因座。我们的数据证实，11q13 处的扩增子可以覆盖大部分 DNA，并且与多个扩增核心的存在相一致。如前所述，一个重要的核心似乎是以 PRAD1/CCND1 为中心； 57 个肿瘤 (14.7%) 显示 PRAD1/CCND1 单独扩增（一个肿瘤）或与 BCL1 或 INT2/FGF3 一起扩增。 PRAD1/CCND1 的扩增水平有时超过周围标记。还检测到与 PRAD1/CCND1 扩增无关的另外三个扩增事件。 BCL1 着丝粒、D11S97 和 D11S146 探针在 60 个肿瘤 (15.4%) 中检测到扩增，并且通常是唯一的扩增标记。 INT2/FGF3 的端粒 D11S833E 在 10 个肿瘤中单独扩增，并且是另外 6 个肿瘤中扩增最多的标记物。在 INT2/FGF3 距离较短的情况下，EMS1 是两个肿瘤中唯一扩增的标记物，其扩增水平可能超过 PRADI/CCND1 和 D11S833E。因此，我们的数据表明乳腺癌中 11q13 条带内存在四个独立的扩增区域。 (C) 1994 年 Wiley-Liss 公司
In an attempt to verify the nature of amplification events at band q13 on chromosome 11 we surveyed the amplification status of ten molecular markers specific for this region (GSTP, SEA, D11S97, D11S146, BCL1, PRAD1/CCND1, HST/FGF4, INT2/FGF3, EMS1, and D11S833E) in a panel of 389 primary breast carcinoma DNA samples. Eighty-eight tumors (23%) showed at least one of these markers amplified, but in a majority of the cases amplification encompassed more than one of the tested loci. Our data confirm that amplicons at 11q13 can cover large portions of DNA and are consistent with the existence of several cores of amplification. One important core seems to be, as previously described, centered around PRAD1/CCND1; 57 tumors (14.7%) showed amplification at PRAD1/CCND1 either alone (one tumor) or along with amplification of BCL1 or INT2/FGF3. The level of amplification of PRAD1/CCND1 sometimes exceeded that of surrounding markers. Three additional amplification events occurring independently of amplification of PRAD1/CCND1 were also detected. Centromeric to BCL1, probes to D11S97, and D11S146 detected amplification in 60 tumors (15.4%) and were often the only amplified markers. Telomeric to INT2/FGF3, D11S833E was found amplified alone in ten tumors, and it was the most amplified marker in another six cases. At a shorter distance of INT2/FGF3, EMS1 was the only amplified marker in two tumors, with a level of amplification that could exceed that of PRADI/CCND1 and D11S833E. Our data thus suggest the existence of four independent amplified regions within band 11q13 in breast cancer. (C) 1994 Wiley-Liss, Inc.